Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04520074 |
| Other study ID # |
FDUSCC-ACTS2 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
Phase 3
|
| First received |
|
| Last updated |
|
| Start date |
October 8, 2021 |
| Est. completion date |
September 2030 |
Study information
| Verified date |
July 2022 |
| Source |
Fudan University |
| Contact |
zhong zheng, dr |
| Phone |
862164175590 |
| Email |
alizheng[@]126.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after
first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy. There is
no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. We developed an
adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step) 6cycle and
CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to
verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.
Description:
More than 70 percent of ovarian cancer patients were diagnosed in the advanced stage.
Currently the 5-year disease free survival (DFS) of stageⅢ-Ⅳovarian cancer patients was about
10 percent after first line chemotherapy. Dr Cai shumo developed adjuvant chemotherapy of
"three steps" (ACTS) for advanced ovarian cancer after cytoreductive surgery, based on his
60+ years experience on gynecologic oncology. After the first step 6-8 cycle paclitaxel plus
carboplatin chemotherapy, the chemo-sensative cancer cells were killed, but
resistant/dormancy cell remained. The second step chemotherapy which is 6 cycle CTX+VP-16
every 4weeks, using different mechanism to kill cancer cells, may decrease the rate of
recurrence within 6 month after first step chemotherapy, prolong platinum-free duration and
also with acceptable side effects. After second step chemotherapy, in absence of 6 months
platinum treatment, the previous G0 dormancy cell may become flexible to platinum treatment.
Therefore, in the third step chemotherapy, CTX+CBP is used in every 8 week for 6 cycles.
Comparing to using targeted therapy for maintaining therapy, the ACTS cost less.
In the previous observation study(CHINA ONCOLOGY 2013 Vol.23 No.12 p980), In study arm A, the
patients received three-step chemotherapy after primary debulking surgery, step one with
paclitaxel plus carboplatin (TC regimen), every 3 weeks for 6 to 8 cycles; step two with
etoposide plus cyclophosphamide, every 4 weeks for 6 cycles; step three with carboplatin plus
cyclophosphamide every eight weeks for six cycles. In control arm B, investigators
retrospectively analysed 51 cases withⅢC-Ⅳstage ovarian cancer, who had completely response
after standard chemotherapy with six to eight cycles of TC after primary surgery during 2007.
Investigators compared the 5-year DFS between the two arms. Results: The 5-year DFS of 15
cases in arm A was 80%(12/15), which was signiifcantly higher than that of arm B (5.9%, 3/51,
P<0.01). Therefore we start this randomized open control clinic trial to evaluated the effect
of ACTS on overall survival and its safety.
In2015, we launched ACTS study (NCT02562365), and the primary results showed benefit of ACTS
on PFS and acceptable AE. Currently, PARP inhibit was shown to be effective in maintainance
therapy in ovarian cancer especially approve for BRCA1/2 mutated pateints. However there is
no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. Here we started ACTS-2
study to verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer
patients.
